News and Events > The University of Colorado Announces a License Agreement with New Fitzsimmons Research Park Company, Proteome Resources LLC

The University of Colorado Announces a License Agreement with New Fitzsimmons Research Park Company, Proteome Resources LLC

Boulder, CO - January, 2005 - The University of Colorado today announced that it has entered into a license agreement with Proteome Resources, LLC., an emerging biosciences company that manufactures and provides biochemistry tools and services for drug discovery and research. The technology license allows Proteome Resources use of unique gene expression and purification technologies developed at CU-Boulder to manufacture unique and high-purity reagents for study of the Ubiquitin-Proteasome System (UPS) in particular, and for the production of highly-purified proteins in general.

The UPS exists in all cells and plays an important role in degrading proteins that control the cell cycle and other critical cellular processes. Malfunctions of the UPS have been linked to several human diseases, including neurodegenerative diseases and cancer. In 2003, the FDA approved the first proteasome-inhibitor drug, Velcade®, which disrupts cancer-cell growth. In 2004, the scientists who discovered the UPS, in the early 1980s, were awarded the Nobel Prize in Chemistry.

"Proteome Resources already has two distribution and one reseller agreement in place, so we're pleased to feel market demand and be part of important research and drug discovery around the ubiquitin-proteasome. We're very pleased to be bringing this CU technology to market," says Randy Swenson, President and CEO of Proteome Resources.

David Allen, CU's Associate Vice President for Technology Transfer, adds, "We are glad to have the opportunity to license this technology to Proteome Resources, who we believe has the capabilities and resources to bring this technology to bear in support of a broad range of customers in the biotechnology marketplace."

Proteome Resources plans to establish operations at the Colorado Bioscience Park Aurora. "We believe Proteome Resources will be a great asset to our research park community at Fitzsimons, and look forward to assisting them as they contribute to the bioscience industry in Colorado," said Vicki Jenings, Director of Research Park Operations for Fitzsimons Redevelopment Authority.


The University of Colorado is a three-campus system with campuses in Boulder and Colorado Springs, and the recently consolidated Denver and Health Sciences Center campuses located in Denver and at the former Fitzsimons Army Base in Aurora. For further information, please contact Michele McKinney in the CU System Office of Institutional Relations at (303) 492-6206.

Proteome Resources is a manufacturer and provider of biochemistry tools and services for drug discovery and research. Currently, the company provides 96 percent-pure enzymes and other reagents (solutions, derivatives, etc.) for study of the ubiquitin-proteasome pathway and the cellular processes that it regulates. These proteins include an inventory of E1 and E2 enzymes, some not available elsewhere. Coming mid-year 2005 will be other ubiquitin enzymes, and many apoptotic nucleases and proteases available on-demand. Company services, available now, include custom cloning and protein expression, with particular expertise in large proteins and high purity. To purchase enzymes or services, or for more information about Proteome Resources, please visit the Proteome web site at http://www.proteomeresources.com.

Colorado's $4.3 billion "Life Sciences City" at Fitzsimons has become the launch pad, hub and focus for the biotechnology industry in the Rocky Mountain Region. The Fitzsimons Redevelopment Authority is responsible for the development of the commercial components at Fitzsimons, including the Colorado Bioscience Park Aurora, the first university-affiliated "biopark" to be developed west of the Mississippi. The Bioscience Park is adjacent to the University of Colorado Health Sciences Center and Hospital Complex, The Children's Hospital, and the Fitzsimons Commons town center. Together, these developments form a stimulating and interactive scientific entrepreneurial community.